<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2021-30-53-56</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-2299</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СОВРЕМЕННАЯ ЛАБОРАТОРИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MODERN LABORATORY</subject></subj-group></article-categories><title-group><article-title>Способ диагностики неалкогольного стеатоза печени</article-title><trans-title-group xml:lang="en"><trans-title>Method for diagnosing non-alcoholic liver steatosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7802-4796</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Булатова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bulatova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Булатова Ирина Анатольевна, д. м. н., доцент, зав. кафедрой нормальной физиологии, проф. кафедры факультетской терапии № 2, профессиональной патологии и клинической лабораторной диагностики</p><p>г. Пермь</p></bio><bio xml:lang="en"><p>Bulatova Irina A., DM Sci (habil.), head of Dept of Normal Physiology, professor of Dept of Faculty Therapy No. 2, Occupational Pathology and Clinical Laboratory Diagnostics</p><p>Perm</p></bio><email xlink:type="simple">bula.1977@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9149-6328</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мифтахова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Miftakhova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мифтахова Альбина Малетьяновна, аспирант кафедры патологической физиологии</p><p>г. Пермь</p></bio><bio xml:lang="en"><p>Miftakhova Albina M., postgraduate student of Dept of Pathological Physiology</p><p>Perm</p></bio><email xlink:type="simple">albinamiftahova91@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7521-1732</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуляева</surname><given-names>И. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Gulyaeva</surname><given-names>I. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гуляева Инна Леонидовна, д. м. н., доцент, зав. кафедрой патологической физиологии</p><p>г. Пермь</p></bio><bio xml:lang="en"><p>Gulyaeva Inna L., DM Sci (habil.), professor, head of Dept of Pathological Physiology</p><p>Perm</p></bio><email xlink:type="simple">pimenova774@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Пермский государственный медицинский университет имени академика Е. А. Вагнера» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical University n. a. academician E. A. Wagner</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>01</day><month>12</month><year>2021</year></pub-date><volume>1</volume><issue>30</issue><issue-title>Современная лаборатория (2)</issue-title><fpage>53</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Булатова И.А., Мифтахова А.М., Гуляева И.Л., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Булатова И.А., Мифтахова А.М., Гуляева И.Л.</copyright-holder><copyright-holder xml:lang="en">Bulatova I.A., Miftakhova A.M., Gulyaeva I.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/2299">https://www.med-alphabet.com/jour/article/view/2299</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Разработка неинвазивного способа диагностики неалкогольного стеатоза печени (НАСП).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Обследован 21 пациент с подтвержденным НАСП при ультразвуковом исследовании со средним возрастом 42,1 ± 10,1 года. Группу контроля составили 10 практически здоровых лиц. Определяли следующие показатели – индекс массы тела (ИМТ), уровень гамма-глутамилтранспептидазы (ГГТП), васкулоэндотелиального фактора роста (ВЭФР) и интерлейкина-6 (ИЛ-6) в сыворотке крови и рассчитывали индекс стеатоза (ИС) с помощью формулы ИС = –1,2390 + 0,0575 × ИМТ + 0,0064 × ГГТП + 0,0006 × ВЭФР + 0,0001 × ИЛ-6. В качестве зависимой переменной был использован показатель наличия стеатоза печени по данным УЗИ печени.</p></sec><sec><title>Результаты</title><p>Результаты. По результатам обследования у пациентов со стеатозом ИМТ и сывороточные концентрации ГГТП, ВЭФР и ИЛ-6 были значимо выше, чем в контрольной группе (р &lt; 0,001; р &lt; 0,001; р &lt; 0,001 и р &lt; 0,001 соответственно), что свидетельствует о наличии синдрома холестаза, признаков воспаления и дисфункции эндотелия. Коэффициент корреляции между значением ИМТ и наличием НАСП составил 0,90; между ГГТП и наличием стеатоза – 0,80; между ВЭФР и наличием стеатоза – 0,85; между ИЛ-6 и наличием стеатоза – 0,80. Предсказательную ценность каждого параметра модели оценивали по шкале значений площади под ROC-кривой (AUC). Модель эффективна (коэффициент множественной корреляции R = 0,809; доля влияния суммы входящих в модель факторов составляет R2 • 100 = 65,5%), статистически значима (критерий F = 12,318; p &lt; 0,0001) и обладает отличными диагностическими характеристиками.</p></sec><sec><title>Заключение</title><p>Заключение. Предложенный неинвазивный метод позволяет диагностировать стеатоз печени с чувствительностью 95,2% и специфичностью 97,0%: при ИС, равном 0,5 и более, диагностируют наличие НАСП, при ИС менее 0,5 – отсутствие.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. Development of a non-invasive method for the diagnosis of non-alcoholic hepatic steatosis.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study involved 21 patients with confrmed non-alcoholic hepatic steatosis on ultrasound examination with an average age of 42.1 ± 10.1 years. The control group consisted of 10 apparently healthy individuals. The following indicators were determined: body mass index (BMI), the level of gamma-glutamyl transpeptidase (GGTP), vasculoendothelial growth factor (VEGF) and interleukin-6 (IL-6) in serum, and the steatosis index (IS) was calculated using the formula IS = –1.2390 + 0.0575 × BMI + 0.0064 × GGTP +0.0006 × VEGF + 0.0001 × IL-6. The index of the presence of hepatic steatosis according to liver ultrasound data was used as a dependent variable.</p></sec><sec><title>Results</title><p>Results. According to the examination results, BMI and serum concentrations of GGTP, VEGF, and IL-6 in patients with steatosis were signifcantly higher than in the control group (p &lt; 0.001, p &lt; 0.001, p &lt; 0.001, and p &lt; 0.001, respectively), which indicates the presence of cholestasis syndrome, signs of inﬂammation and endothelial dysfunction. The correlation coeffcient between BMI and the presence of non-alcoholic hepatic steatosis was 0.9; between GGTP and the presence of steatosis was 0.80; between VEGF and the presence of steatosis was 0.85; between IL-6 and the presence of steatosis was 0.80. The predictive value of each parameter of the model was assessed using a scale of values of the area under the ROC-curve (AUC). The model is effective (multiple correlation coeffcient R = 0.809; the share of the inﬂuence of the sum of the factors included in the model is R2 • 100 = 65.5%), statistically signifcant (criterion F = 12.318; p &lt; 0.0001) and has excellent diagnostic characteristics.</p></sec><sec><title>Conclusion</title><p>Conclusion. The proposed non-invasive method makes it possible to diagnose hepatic steatosis with a sensitivity of 95.2% and a specifcity of 97.0%: with IS equal to 0.5 or more, the presence of non-alcoholic hepatic steatosis is diagnosed, with IS less than 0.5 is not.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольный стеатоз печени</kwd><kwd>индекс стеатоза</kwd><kwd>васкулоэндотелиальный фактор роста</kwd><kwd>интерлейкин-6</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic hepatic steatosis</kwd><kwd>steatosis index</kwd><kwd>vasculoendothelial growth factor</kwd><kwd>interleukin-6</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., М.В. Маевская, Ч.С. Павлов и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2016: (2): 24–42. https://doi.org/10.22416/1382–4376–2016–26–2–24–42</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., M.V. Mayevskaya, Ch.S. Pavlov et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2016: (2): 24–42. https://doi.org/10.22416/1382–4376–2016–26–2–24–42</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В. Т. и соавт. Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей. В.Т. Ивашкин. Москва. 2015. 29 с.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T. et al. Diagnostics and treatment of non-alcoholic fatty liver disease: guidelines for doctors. V.T. Ivashkin. Moscow. 2015. 29 p.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bedogni G., Miglioli L., Masutti F. et al. Incidence and natural course of fatty liver in the general population: The Dionysos study. Hepatology. 2007: (46): 1387–1391.</mixed-citation><mixed-citation xml:lang="en">Bedogni G., Miglioli L., Masutti F. et al. Incidence and natural course of fatty liver in the general population: The Dionysos study. Hepatology. 2007: (46): 1387–1391.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мохорт Т.В. Неалкогольная жировая болезнь печени и сахарный диабет: аспекты патогенеза, диагностики и лечения. Медицинские новости. 2012: (4): 4–10.</mixed-citation><mixed-citation xml:lang="en">Mohort T.V. Non-alcoholic fatty liver disease and diabetes mellitus: aspects of pathogenesis, diagnosis and treatment. Medical news. 2012: (4): 4–10.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Poynard T., Lassailly G., Diaz E., Clement K. et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta-analysis of individual patient data. PLoS One. 2012: 7 (3): e30325. https://doi.org/10.1371/journal.pone.0030325</mixed-citation><mixed-citation xml:lang="en">Poynard T., Lassailly G., Diaz E., Clement K. et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta-analysis of individual patient data. PLoS One. 2012: 7 (3): e30325. https://doi.org/10.1371/journal.pone.0030325</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaguchi K., Yang L., McCall S. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fbrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007: (45): 1366–1374. DOI: 10.1002/hep.21655.</mixed-citation><mixed-citation xml:lang="en">Yamaguchi K., Yang L., McCall S. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fbrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007: (45): 1366–1374. DOI: 10.1002/hep.21655.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fbrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013; 19 (8): 1219–1229. PMID: 23482703. DOI: 10.3748/wjg.v19.i8.1219.</mixed-citation><mixed-citation xml:lang="en">Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fbrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013; 19 (8): 1219–1229. PMID: 23482703. DOI: 10.3748/wjg.v19.i8.1219.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Шелудько В. С. Теоретические основы медицинской статистики: метод. рекомендации. В.С. Шелудько, М.Я. Подлужная. Пермь, 2001. 36 с.</mixed-citation><mixed-citation xml:lang="en">Sheludko V.S. Theoretical foundations of medical statistics: method. Recommendations. VS Sheludko, M. Ya. Podluzhnaya. Perm, 2001. 36 p.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Власов В.В. Эффективность диагностических исследований. В.В. Власов. М.: Медицина, 1988. 256 с.</mixed-citation><mixed-citation xml:lang="en">Vlasov V.V. Effciency of diagnostic studies. V.V. Vlasov. M.: Medicine, 1988. 256 p.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kugelmas M., Hill D.B., Vivian B., Marsano L., McClain C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modifcation and vitamin E. Hepatology. 2003: 38 (2): 413–419. DOI: 10.1053/jhep.2003.50316.</mixed-citation><mixed-citation xml:lang="en">Kugelmas M., Hill D.B., Vivian B., Marsano L., McClain C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modifcation and vitamin E. Hepatology. 2003: 38 (2): 413–419. DOI: 10.1053/jhep.2003.50316.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Abiru S., Migita K., Maeda Y. et al. Serum cytokine and soluble cytokine receptor levels in patients with nonalcoholic steatohepatitis. Liver Int. 2006: 26 (1): 39–45. DOI: 10.1111/j.1478–3231.2005.01191.x.</mixed-citation><mixed-citation xml:lang="en">Abiru S., Migita K., Maeda Y. et al. Serum cytokine and soluble cytokine receptor levels in patients with nonalcoholic steatohepatitis. Liver Int. 2006: 26 (1): 39–45. DOI: 10.1111/j.1478–3231.2005.01191.x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Пивторак Е.В. Нарушения функции эндотелия у больных неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2014: (2): 63.</mixed-citation><mixed-citation xml:lang="en">Pivtorak E.V. Endothelial dysfunction in patients with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2014: (2): 63.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cetindaglı I., Kara M., Tanoglu A., Ozalper V., Aribal S., Hancerli Y., Unal M., Ozarı O., Hira S., Kaplan M., Yazgan Y. Evaluation of endothelial dysfunction in patients with nonalcoholic fatty liver disease: Association of selenoprotein P with carotid intima-media thickness and endothelium-dependent vasodilation. Clinics and Research in Hepatology and Gastroenterology. 2017: 28 (3): 290–291. DOI: 10.1016/j.clinre.2017.01.005. Epub 2017 Jul 29.</mixed-citation><mixed-citation xml:lang="en">Cetindaglı I., Kara M., Tanoglu A., Ozalper V., Aribal S., Hancerli Y., Unal M., Ozarı O., Hira S., Kaplan M., Yazgan Y. Evaluation of endothelial dysfunction in patients with nonalcoholic fatty liver disease: Association of selenoprotein P with carotid intima-media thickness and endothelium-dependent vasodilation. Clinics and Research in Hepatology and Gastroenterology. 2017: 28 (3): 290–291. DOI: 10.1016/j.clinre.2017.01.005. Epub 2017 Jul 29.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Борсуков А. В., Морозова Т. Г., Венидиктова Д. Ю., Иванов Ю. В. Способ диагностики стеатоза печени. Патент RU2648 183 C1. 2018. Опубликовано 22.03.2018 Бюл. № 9. https://patenton.ru/patent/RU2648183C1.pdf</mixed-citation><mixed-citation xml:lang="en">Borsukov A.V., Morozova T.G., Venidiktova D. Yu., Ivanov Yu.V. Method for diagnosing liver steatosis. Patent RU2648 183 C1. 2018 Published 22.03.2018. Bul. No. 9. https://patenton.ru/patent/RU2648183C1.pdf</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
